Genprex to Present at NobleCon17 on January 19
AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the NobleCon17, Noble Capital Markets’ Annual Investor Conference, taking place virtually January 19-20. Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming clinical trials, to participating investors.
Presentation Date: Tuesday, January 19
Presentation Time: 3:45 p.m. EST – Track 1
Registration Link: https://bit.ly/3oAVY1c